Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Mr. Ron Chapman II, a top legal mind in healthcare compliance and opioid litigation

Mr. Ron Chapman II began his career as an officer in the U.S. Marine Corps and was deployed to combat in Afghanistan. He achieved the rank of Captain before transitioning to law.

He graduated from Loyola School of Law, where he received his Master of Laws (LL.M.) with a concentration in health care compliance.

He quickly established himself as a premier healthcare defense counsel, and is among the few attorneys to have achieved trial acquittals on behalf of clients charged with healthcare financial fraud or improper opioid prescribing.

He now shares his wisdom and learned experiences in the book – Fight the Feds: Unraveling Federal Criminal Investigations. To purchase his book, please select the link below:

To learn more about Mr. Chapman’s legal work and his firm, Chapman Law Group, please select the link below:

https://www.chapmanlawgroup.com/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!